Along with Threshold Pharmaceuticals Inc. (NASDAQ:THLD), Galena was the best performing stock in the market, during the first quarter. It traded with excessive loss during the second quarter, and has returned large consistent gains in Q3. The stock is now maintaining gains, trading with less volatility, but has continued to trade higher since its Q2 price dip.
So why is Galena worth watching in the final two months of 2012? The company is expected to present possible share-price moving data in the coming weeks. Back during ASCO 2012, the company announced booster data for its Phase II trial of 187 patients.